Abstract
Major depressive disorder (MDD) is a common, recurrent mental illness that affects millions of people worldwide. Accumulating evidence suggests that the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptors, plays an important role in the neurobiology and treatment of this disease. Currently, the non-competitive NMDA receptor antagonist ketamine is considered as one of the most attractive candidate drugs in therapy of treatment-resistant depression. A recent study demonstrated ketamine's rapid antidepressant activity in patients with treatment-resistant MDD and bipolar disorder. The response rate for ketamine ranged from 25% to 85% at 24 hours post-infusion and from 14% to 70% at 72 hours post-infusion, with generally mild adverse effects. Based on the role of the NMDA receptor in depression, a number of therapeutic drugs which interact with this receptor have been developed. In this article, we reviewed recent findings concerning the role of glutamatergic signaling in the neurobiology of MDD and potential, novel therapeutic drugs, such as ketamine, memantine, AZD6765, traxoprodil, MK-0657, GLYX-13, NRX-1047, D-cycloserine, sarcosine, all of which target this system.
Keywords: Depression, glutamate, NMDA receptors, GluN2B subtype, ketamine, treatment-resistant.
Current Pharmaceutical Design
Title:Targeting of NMDA Receptors in the Treatment of Major Depression
Volume: 20 Issue: 32
Author(s): Yong-Hui Dang, Xian-Cang Ma, Ji-Chun Zhang, Qian Ren, Jin Wu, Cheng-Ge Gao and Kenji Hashimoto
Affiliation:
Keywords: Depression, glutamate, NMDA receptors, GluN2B subtype, ketamine, treatment-resistant.
Abstract: Major depressive disorder (MDD) is a common, recurrent mental illness that affects millions of people worldwide. Accumulating evidence suggests that the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptors, plays an important role in the neurobiology and treatment of this disease. Currently, the non-competitive NMDA receptor antagonist ketamine is considered as one of the most attractive candidate drugs in therapy of treatment-resistant depression. A recent study demonstrated ketamine's rapid antidepressant activity in patients with treatment-resistant MDD and bipolar disorder. The response rate for ketamine ranged from 25% to 85% at 24 hours post-infusion and from 14% to 70% at 72 hours post-infusion, with generally mild adverse effects. Based on the role of the NMDA receptor in depression, a number of therapeutic drugs which interact with this receptor have been developed. In this article, we reviewed recent findings concerning the role of glutamatergic signaling in the neurobiology of MDD and potential, novel therapeutic drugs, such as ketamine, memantine, AZD6765, traxoprodil, MK-0657, GLYX-13, NRX-1047, D-cycloserine, sarcosine, all of which target this system.
Export Options
About this article
Cite this article as:
Dang Yong-Hui, Ma Xian-Cang, Zhang Ji-Chun, Ren Qian, Wu Jin, Gao Cheng-Ge and Hashimoto Kenji, Targeting of NMDA Receptors in the Treatment of Major Depression, Current Pharmaceutical Design 2014; 20 (32) . https://dx.doi.org/10.2174/1381612819666140110120435
DOI https://dx.doi.org/10.2174/1381612819666140110120435 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Conference Report: 8<sup>th</sup> Clinical Trials on Alzheimer Disease (CTAD), Barcelona, Spain November 5-7, 2015
CNS & Neurological Disorders - Drug Targets The Role of Metabolizing Enzymes and Transporters in Antiretroviral Therapy
Current Topics in Medicinal Chemistry Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Therapy Against Ischemic Injury
Current Pharmaceutical Design Mechanistic Insights Into Diabetes Mellitus and Oxidative Stress
Current Medicinal Chemistry Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Tyrosol and Hydroxytyrosol Two Main Components of Olive Oil, Protect N2a Cells Against Amyloid-β-Induced Toxicity. Involvement of the NF-κB Signaling
Current Alzheimer Research Amyloid-Related Biomarkers for Alzheimers Disease
Current Medicinal Chemistry Preservation of Cellular Glutathione Status and Mitochondrial Membrane Potential by N-Acetylcysteine and Insulin Sensitizers Prevent Carbonyl Stress-Induced Human Brain Endothelial Cell Apoptosis
Current Neurovascular Research Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders
Current Topics in Medicinal Chemistry Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease
Current Topics in Medicinal Chemistry New Agents Promote Neuroprotection in Parkinson’s Disease Models
CNS & Neurological Disorders - Drug Targets Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Advanced Tools of Regenerative Medicine for Neurodegenerative Diseases
Recent Patents on Regenerative Medicine Targeting Host Store-Operated Ca<sup>2+</sup> Release to Attenuate Viral Infections
Current Topics in Medicinal Chemistry Effect of Lithium on Neurocognitive Functioning
Current Alzheimer Research Quantitative Machine Learning Analysis of Brain MRI Morphology throughout Aging
Current Aging Science Neuromodulation of Hippocampal Synaptic Plasticity, Learning, and Memory by Noradrenaline
Central Nervous System Agents in Medicinal Chemistry Transthyretin Deposition in Familial Amyloidotic Polyneuropathy
Current Medicinal Chemistry Editorial:Shaping Current and Future Kinase Drug Discovery
Current Topics in Medicinal Chemistry